Content Type: Article

  • Healthcare Enforcement Roundup | Volume 1, 2021

    Healthcare Enforcement Roundup | Volume 1, 2021

    ARTICLE

    Healthcare Enforcement Roundup | Volume 1, 2021

    April 1, 2021

    Read time: 2 min

    Key takeaways
    Overview

    Stay current on the healthcare enforcement issues impacting your business’ compliance strategies. In this installment of the Healthcare Enforcement Roundup, we address:

    • Key areas of enforcement scrutiny in 2021, including growing numbers of relator complaints under the False Claims Act, COVID-19-related enforcement, and ongoing attention to private equity;
    • Timely updates on Section 1135 waivers, telemedicine-related issues, and further interpretation regarding the enforceability of sub-regulatory guidance;
    • The Office of Inspector General’s Special Fraud Alert, which provides important guidelines for pharmaceutical and medical device speaker programs; and
    • Pertinent developments in cases and other enforcement matters covered in prior issues.
    In depth
    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    Marshall E. Jackson , Jr.

    Partner

    Washington, DC

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Lisa Mazur

    Partner

    Chicago

    Laura McLane

    Partner

    Boston

    Paul M. Thompson

    Partner

    Washington, DC

    Dexter Golinghorst

    Associate

    Chicago

    MaryKathryn Hurd

    Senior Knowledge Management Manager

    Washington, DC

    Caroline Reignley

    Partner

    Washington, DC

    More insights

  • Key Takeaways and Q&A | Return to Work Virtual Toolkit for Employers | Remote Work Considerations

    Key Takeaways and Q&A | Return to Work Virtual Toolkit for Employers | Remote Work Considerations

    ARTICLE

    Key Takeaways and Q&A | Return to Work Virtual Toolkit for Employers | Remote Work Considerations

    April 1, 2021

    Read time: 2 min

    Key takeaways
    Overview

    As COVID-19 vaccines continue to roll out across the United States, many employers that shifted to remote work environments at the onset of the COVID-19 pandemic still have employees working from home. While some employers intend to transition back to the regular workplace once the environment improves, many intend to maintain a remote workforce for the longer term. And, although remote work arrangements increase talent pools and enhance flexibility for current employees, they create a number of employment and tax challenges for employers.

    Our webinar included a discussion of formal policies employers should have in place, strategies to avoid the inevitable surge in wage and hour litigation and tax implications for employers with remote out-of-state employees, as well as a Q&A session.

    Watch the “How Employers Should Prepare for the End of the COVID-19 National and Public Health Emergencies” webinar recording to learn more.

    In depth
    Authors

    Joseph Mulherin

    Partner

    Chicago

    Troy M. Van Dongen

    Partner

    San Francisco

    More insights

  • Broker-Dealers and Mutual Funds: Increased Regulatory Focus on Suspicious Activity Monitoring and Reporting Requirements

    Broker-Dealers and Mutual Funds: Increased Regulatory Focus on Suspicious Activity Monitoring and Reporting Requirements

    ARTICLE / CLIENT ALERT

    Broker-Dealers and Mutual Funds: Increased Regulatory Focus on Suspicious Activity Monitoring and Reporting Requirements

    April 1, 2021

    Read time: 9 min

    Key takeaways
    Overview

    Congress’ enactment of the Anti-Money Laundering Act of 2020 (“AML Act”) and Corporate Transparency Act (“CTA”), both part of the National Defense Authorization Act of 2021, resulted in some of the most significant reforms to the Bank Secrecy Act (“BSA”) and federal anti-money laundering (“AML”) laws since the USA PATRIOT Act of 2001.[1] While the full impact of this recent legislation will not be fully realized until the U.S. Department of the Treasury’s Financial Crimes Enforcement Network (“FinCEN”) adopts implementing regulations,[2] we are already seeing increased scrutiny by the U.S. Securities and Exchange Commission (“SEC”) and securities industry self-regulatory organizations (“SROs”), including the Financial Industry Regulatory Authority (“FINRA”), of firms’ compliance with AML program obligations, including suspicious activity monitoring and reporting.

    On March 29, 2021, the staff of the SEC’s Division of Examinations (“SEC Exam Staff”) reminded broker-dealers and mutual funds of their obligations under AML rules and regulations[3] and highlighted AML compliance-related deficiencies that they observed during the most recent SEC examination cycle (“AML Risk Alert”). This AML Risk Alert focuses on the SEC Exam Staff’s observations of inadequacies regarding broker-dealers’ policies and procedures to identify and report suspicious activity, inadequate implementation of reasonably designed procedures to respond to suspicious activity, and the filing of incomplete or inaccurate suspicious activity reports (“SARs”).

    AML Policies, Procedures and Internal Controls

    The SEC Exam Staff continues to examine broker-dealers that have not established AML policies, procedures and internal controls that are reasonably designed to identify and report suspicious activity as required under the Bank Secrecy Act, and its implementing regulations, including:

    • Failing to tailor red flags to the types of activity in which their clients regularly engage or to sufficiently detail red flags in their policies and procedures;
    • Failing to implement automated systems to monitor large trading volumes;
    • Failing to monitor low-priced securities transactions where securities are priced between $1 and $5 or where the transaction occurs on an exchange;
    • Setting SAR reporting thresholds above $5,000; and
    • Inappropriate reliance by introducing firms on clearing firms to identify and report suspicious transactions in customer accounts and failing to adopt their own procedures that take into account the high-risk nature of their customers’ activity, e.g., trades in low-priced, unregistered securities.[4]

    The SEC Exam Staff also observed that some firms had reasonably designed policies and procedures related to suspicious activity, but failed to adequately implement them, including by:

    • Making inconsistent determinations to file SARs;
    • Failing to utilize available reports and monitoring systems;
    • Inadequately following up on red flags identified in their procedures (such as prearranged or non-completive trading, including wash or cross trades or potential insider trading); and
    • Failing to adhere to firm policies regarding prohibitions against certain high-risk activity (e.g., accepting trades for securities less than one penny per share without adequate due diligence).

    Suspicious Activity Monitoring and Reporting

    The SEC Exam Staff observed that many firms failed to adequately conduct or document due diligence in response to known indicators of suspicious activity,[5] especially with respect to activity in low-priced securities, and that firms failed to account for publicly available information about their customers when conducting due diligence, including failing to:

    • Identify sales of shares that were publicly known to be part of promotional activity;
    • Link trading in low-priced securities to customers who were publicly known to be affiliated with the issuer; and
    • Identify concentrations of low-priced security liquidations among clients of high-risk introducing broker-dealers or broker-dealer counterparties.

    Lastly, the SEC Exam Staff raised concerns that firms continue to file SARs with inaccurate information or that lack sufficient detail. Of particular concern are:

    • Failing to include in SAR reports key information that is available in the firm’s internal records (“e.g., social security numbers, dollar amounts for customers’ losses from identity theft and account-takeover fraud, customers’ disciplinary history and account numbers, details relating to foreign customers and sub-accountholders and concerns about suspected promoters and issuers of low-priced securities”);
    • Reporting only one leg of a suspicious transaction (e.g., the deposit but not the liquidation of low-priced securities); and
    • Failing to adequately detail cyber-intrusions in SAR reports (e.g., the method and manner of cyber-intrusions and schemes to “take over” customer accounts, including the method of transferring out funds, how the account was accessed, bank account information, phone/fax numbers, email addresses and IP addresses).[6]

    In addition to enhanced SEC scrutiny, FINRA continues to aggressively enforce AML rules against its members and has provided additional guidance concerning broker-dealer AML obligations, including the potential for suspicious activity related to low-priced securities or “penny stocks.”[7] Specifically, in February 2021, FINRA published a notice urging firms to review their policies and procedures relating to red flags involving low-priced securities transactions, which it emphasized can be volatile and particularly vulnerable to fraud and market manipulation.[8] FINRA noted that bad actors often perpetrate illegal activity by taking advantage of trends or major events such as growth in cannabis-related businesses or the ongoing COVID-19 pandemic. FINRA advised that firms could mitigate these risks by strengthening their controls to detect, monitor, and report potentially fraudulent low-priced securities activity and identified issuer-, promotional- and customer-specific red flags, as well as specific monitoring and other supervisory controls that broker-dealers can implement to mitigate the risk of these frauds and to detect and report the activity.

    In March 2021, FINRA issued a special alert regarding its near real-time observation of a sharp increase in “instant funds” abuse.[9] Instant funds abuse typically involves new customers opening online brokerage accounts with immediate access to funds and placing securities orders before their account is funded, allowing those customers to engage in fraudulent transactions before the brokerage firm receives a notice of fraud or insufficient funds from the funding bank, resulting in losses to the brokerage firm. Notably, this notice was published, at least in part, based on FINRA’s observation of discussions occurring on social media regarding the instant funds policies of specific firms.[10] FINRA urged firms to mitigate this risk by adjusting the amount of available instant funds, delaying the ability to place orders with unsettled funds, or enhancing account validation processes. These alerts signal that FINRA expects firms to be regularly assessing potential financial risks, taking swift action to mitigate and address them and conducting meaningful due diligence as to whether a SAR should be filed.

    The SEC Exam Staff, citing SEC v. Alpine Securities Corp., notes that a broker-dealer’s failure to file a SAR or maintain records as required by the SAR rule would be a violation of Section 17(a) of the Exchange Act and Rule 17a-8.[11] The SEC Exam Staff also notes that “[a] broker-dealer’s failure to follow its own AML procedures could also constitute a failure to ‘document accurately’ its AML compliance program in violation of Section 17(a) and Rule 17a-8.”[12]

    Conclusion

    AML continues to be an examination priority for the SEC[13] and various SROs.[14] Firms should expect increased scrutiny by regulators of their AML compliance programs and, in particular, their suspicious activity reporting procedures. Regulators are also focused on market manipulation, issues relating to low-priced securities, including unregistered distributions, and the use of social media and online message boards to disrupt the market and perpetuate fraud. Firms should expect that AML deficiencies will result in substantial and increasing regulatory penalties. Accordingly, firms should continue to proactively review and, as necessary, enhance their AML programs to ensure that their policies, procedures, and internal controls are tailored to their specific business risks, appropriately implemented, and that their SAR-filing procedures satisfy applicable law and industry guidance, including that they are accurate and appropriately detailed.

    Authored by Betty Santangelo, Julian Rainero, Craig S. Warkol, Melissa G.R. Goldstein, Derek N. Lacarrubba, Kolby Loft and J. Eric Prather.

    If you have any questions concerning this Alert, please contact your attorney at Schulte Roth & Zabel or one of the authors.


    [1] See SRZ’s previous Alert regarding the substance of these reforms.

    [2] On April 1, 2021, FinCEN issued an Advance Notice of Proposed Rulemaking (“ANPRM”) to solicit public comment on a wide range of questions related to the implementation of the beneficial ownership information reporting provisions of the CTA, commencing its rulemaking efforts. The ANPRM is scheduled to be published in the Federal Register on April 5, 2021. View an unpublished version of the ANPRM.

    [3] Securities and Exchange Commission, Division of Examinations, Risk Alert: Compliance Issues Related to Suspicious Activity Monitoring and Reporting at Broker-Dealers (March 29, 2021).

    [4] See also “Frequently Asked Questions (FAQ) regarding Anti-Money Laundering (AML),” FINRA (March 29, 2021).

    [5] See “FINRA Provides Guidance to Firms Regarding Suspicious Activity Monitoring and Reporting Obligations,” Reg. Notice 19-18, FINRA (May 6, 2019) for FINRA guidance regarding suspicious activity monitoring.

    [6] See SRZ’s Alert regarding the increased cybersecurity risks arising from the COVID-19 pandemic for more information.

    [7] See 17 C.F.R. § 240.3a51-1 (defining “penny stock”).

    [8] See “FINRA Urges Firms to Review Their Policies and Procedures Relating to Red Flags of Potential Securities Fraud Involving Low-Priced Securities,” Reg. Notice 21-03, FINRA (Feb. 10, 2021).

    [9] “FINRA Alerts Firms to Recent Increase in ACH ‘Instant Funds’ Abuse,” Reg. Notice 21-14, FINRA (March 25, 2021).

    [10] FINRA noted that the increase “appeared correlated to the recent market volatility driven by social media interest in certain securities.” Id. Though FINRA did not identify any particular social media platform or source, the FINRA observation period coincided with prominent short squeezing activities by members of the “wallstreetbets” Reddit group. See SRZ’s Alert regarding the recent short squeezes for more information.

    [11] Securities and Exchange Commission, Division of Examinations, Risk Alert: Compliance Issues Related to Suspicious Activity Monitoring and Reporting at Broker-Dealers, at 2, n.4 (March 29, 2021) (citing SEC v. Alpine Securities Corp., 982 F.3d 68 (2d Cir. 2020)).

    [12] Id.

    [13] See Securities and Exchange Commission, Division of Examinations, 2021 Examination Priorities (March 3, 2021).

    [14] See, e.g., 2021 Report on FINRA’s Examination and Risk Monitoring Program, FINRA (Feb. 1, 2021).


    This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2021 Schulte Roth & Zabel LLP.

    All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

    In depth
    Authors

    Betty Santangelo

    Counsel

    New York – 919 Third Avenue

    Melissa G.R. Goldstein

    Partner

    New York – 919 Third Avenue

    J. Eric Prather

    Associate

    New York – 919 Third Avenue

    More insights

  • Assigning Responsibility During Covid and Beyond: Contractual Burdens of Proof

    ARTICLE

    Assigning Responsibility During Covid and Beyond: Contractual Burdens of Proof

    March 20, 2021

    Read time: 1 min

    Key takeaways
    Overview

     

     

    In depth
    Authors
    More insights

  • Colourful Non-functionality Argument Misses the (Design) Mark

    ARTICLE

    Colourful Non-functionality Argument Misses the (Design) Mark

    March 31, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights

  • CMS Restarts Hospital Survey Activities Delayed by COVID-19

    CMS Restarts Hospital Survey Activities Delayed by COVID-19

    ARTICLE / CLIENT ALERT

    CMS Restarts Hospital Survey Activities Delayed by COVID-19

    March 31, 2021

    Read time: 4 min

    Key takeaways
    Overview

    The Centers for Medicare and Medicaid Services (CMS) notified state survey agency directors that it has lifted previously imposed hospital survey suspensions and resumed routine hospital reaccreditation and recertification surveys, complaint investigations and enforcement activities as of March 26, 2021.

    In depth

    CMS issued a Quality, Safety & Oversight Group and Survey & Operations Group memorandum addressed to state survey agency directors on March 26, 2021, effective immediately, outlining the resumption of hospital survey activities following the termination of the previously imposed 30-day suspension.

    The memo (QSO-21-16-Hospitals) directed state survey agencies to follow CMS’s prior guidance regarding survey activities, which CMS circulated in August 2020 and which we previously summarized.

    The memo emphasizes specific guidance that hospitals should keep in mind:

    • Surveyors must investigate non-immediate jeopardy complaints within 45 days of the memo (by May 10, 2021).
    • Providers with open surveys with cited deficiency tags whose requirement to submit a plan of correction was delayed by the prior suspension of surveys must now submit those plans within 10 calendar days of the memo (by April 5, 2021).
    • If providers are unable to complete and implement a plan of correction because of COVID-19 outbreaks in their area, they should contact their state survey agency to request an extension.
    • State surveyors are not obligated to conduct onsite visits or revisits for any level of noncompliance that has been suspended from January 20, 2021, through March 22, 2021, except for unremoved immediate jeopardy situations. This means that remote desk reviews may be conducted on immediate jeopardy citations that have been verified as removed or downgraded to a lower level of noncompliance.
    • As of March 23, 2021, state surveyors are authorized and directed to resume onsite revisits of hospitals demonstrating deficiencies cited in plans of correction when applicable pursuant to State Operations Manual Chapter 2, Section 2732. Generally, onsite visits are required for deficiencies related to quality of care. Remote desk reviews can process many other deficiency citations where evidence of remediation does not require personal observation. Acceptable evidence may include dates of training, attendance rosters, evidence of competency, monitoring for policy implementation and staff adherence to the policy.
    • If state surveyors are concerned about any immediate jeopardy citations cleared with a remote desk review, the clinical area of concern may be included as part of the next onsite survey.
    • Providers with non-immediate jeopardy enforcement actions will have 60-90 days from the memo to demonstrate compliance with any outstanding deficiencies.

    Because COVID-19 remains a public health emergency, CMS has discretion to re-suspend hospital surveys if circumstances require. However, this action forecasts that CMS expects hospitals to continue providing high-quality services to patients, and any continued relaxation of enforcement efforts is likely to be short-lived.

    Key Takeaways

    Hospitals with outstanding survey activities or plans of correction should review the new CMS timelines for review and take immediate action to address outstanding obligations. Hospitals that anticipate ordinary course survey activities (e.g., related to new complaints, or pending survey cycles) should expect those to proceed with onsite survey activity. Major accrediting organizations, including The Joint Commission and DNV, have also announced plans to increase onsite, unannounced survey activity in line with CMS guidance, signaling a return to a robust hospital accreditation and survey environment.

    Authors

    Sandra M. DiVarco

    Partner

    Chicago

    More insights

  • New European Commission Guidance: Acquisitions of Nascent Competitors on the Radar

    New European Commission Guidance: Acquisitions of Nascent Competitors on the Radar

    ARTICLE / CLIENT ALERT

    New European Commission Guidance: Acquisitions of Nascent Competitors on the Radar

    March 31, 2021

    Read time: 6 min

    Key takeaways
    Overview

    The European Commission wants to be able to block or conditionally approve transactions, mainly in the digital economy and in the pharmaceutical sector, even when the thresholds for notification are not met. In publishing its new Article 22 Guidance, the Commission has significantly expanded its ability to review transactions. Parties to a transaction, especially in the digital economy and in the pharma sector, should bear this in mind when strategising on deal timing and any potential remedies. They will also have to take into account the possibility that the transaction will be blocked. For third parties, this opens another possibility to stop a transaction, to extract remedies from the notifying parties or to even roll back an implemented transaction.

    In depth

    What Happened

    • Article 22 of the EU Merger Regulation (EUMR) allows for one or more Member States to request the Commission to examine any merger that does not have an EU dimension but meets the following cumulative conditions: it affects trade between Member States, and it threatens to significantly affect competition within the territory of the Member State or States making the request (Article 22 Conditions). Fulfilment of the Article 22 Conditions ensures that a merger has a sufficient nexus with the European Union and the referring Member State(s).
    • Traditionally, the Commission has discouraged the use of Article 22 EUMR in merger cases that were not notifiable under the laws of the referring Member State(s). This is principally because the Commission considered such transactions unlikely to have a significant impact on the internal market.
    • Recently, however, there has been an increase in the number of mergers involving companies that play, or may develop into playing, a significant competitive role on the market, despite generating little or no turnover at the time of the merger. This development has been found to be particularly significant in the digital economy, where services regularly launch with the aim of building up a significant user base and/or commercially valuable data inventories, before the business is monetised, and in the pharma sector, where transactions have involved innovative companies conducting R&D with strong competitive potential, even if such companies have not yet finalised, let alone exploited commercially, the results of their R&D activities. Because of the absence of, or low, turnover of one the parties to such transactions, they invariably escape assessment under national merger control rules.
    • With a view ensuring that non-notifiable yet potentially problematic mergers do not fly under the radar of merger control review, on 26 March 2021 the Commission issued practical guidance (Article 22 Guidance) on when it might be appropriate for a Member State to refer such mergers to the Commission for merger control review.

    What This Means

    • The Commission encourages, and is more amenable to (discretionally) accepting, referrals in cases where the referring Member State does not have initial jurisdiction over a case, but where the Article 22 Conditions are met, particularly in, although not necessarily limited to, cases involving a transaction where one party:
      – Is a start-up or recent entrant with significant competitive potential that has yet to develop or implement a business model generating significant revenues (or is still in the initial phase of implementing such business model)
      – Is an important innovator or is conducting potentially important research
      – Is an actual or potential important competitive force
      – Has access to competitively significant assets (such as raw materials, infrastructure, data or intellectual property rights)
      – Provides products or services that are key inputs/components for other industries.

    In exercising its discretion whether to encourage or accept a referral, the Commission may also take into account whether the value of the transaction is particularly high compared to the current turn-over of the target.

    What to Bear in Mind

    Transactions involving nascent competitors in particular—especially in (though not strictly limited to) the digital economy and pharma sectors—are likely to increasingly be in the Commission’s crosshairs. Mergers that until recently were unlikely to face antitrust scrutiny because of the absence of, or low, turnover of the target now may be referred upwards to the Commission for merger control review. Henceforth, this risk will have to be factored into any deal timeline.

    With this risk on the horizon, and with a view to avoiding (potentially significant) business disruption, increased prudence is called for. Merging parties may wish to pre-emptively approach the Commission regarding their intended transaction to solicit an early indication of whether the transaction constitutes a candidate for referral under Article 22 EUMR. If the Commission does become aware of a transaction that, in its view, meets the Article 22 Conditions, it may inform the relevant Member State(s) thereof, and invite the State(s) to make a (discretionary) referral request. If the Commission subsequently picks up the referral, implementation of the transaction will have to be put on hold until the Commission gives the green light. Moreover, the fact that a transaction has already been closed does not preclude a Member State from requesting a referral to the Commission — although the Commission is unlikely to look into a transaction where more than six months has passed since its implementation.

    The Article 22 Guidance also gives rise to new opportunities for third parties that have misgivings about a transaction which, up until now, would not have been reviewed and which, absent review, may have a negative impact on their business. It may be, for example, that an aggrieved third party sees that a transaction, which is not prima facie subject to review, will lead to higher prices or risks foreclosing it from the market, in which case it is encouraged to inform the Commission or the competent Member State authority. This may allow a third party pick up any “low-hanging fruit” by positioning itself as a potential purchaser for any remedies that are offered. Even behind the scenes, the mechanism enshrined in the Article 22 Guidance may open doors for third parties to secure strategic concessions from parties to an intended transaction to the extent the parties have not notified the Commission thereof.

    Authors
    More insights

  • Congressional Investigations during the 117th Congress: What to Expect

    Congressional Investigations during the 117th Congress: What to Expect

    ARTICLE / CLIENT ALERT

    Congressional Investigations during the 117th Congress: What to Expect

    March 30, 2021

    Read time: 9 min

    Key takeaways
    Overview

    Although control and leadership of the US House of Representatives did not change hands as a result of the 2020 elections, President Joe Biden’s victory and the Democrats’ Senate runoff victories in Georgia are already having a significant impact on the trajectory of congressional investigations over the next two years. Historically, when Congress and the presidency are controlled by the same party, congressional investigations tend to focus more on the private sector than the Executive Branch. As a result, companies should be aware of issues and industries that are likely targets of investigation and the ways in which congressional inquiries differ from traditional criminal, civil and administrative legal processes and other governmental investigations.

    In depth

    Industries and companies targeted by congressional investigations face unique challenges as law and politics converge, and the investigations often play out under intense media scrutiny. This presents legal, political, reputational and business risks. Successfully navigating these challenges requires familiarity not only with the rules, procedures and precedents of congressional investigations, but also the personalities and priorities of individual committee and subcommittee leaders and rank-and-file members. Failure to manage these risks can lead to significant adverse outcomes, such as the public release of sensitive commercial information, a decline in company value and collateral criminal or civil investigations.

    While congressional Democrats will investigate a wide array of industries and issues, the following are some of those likely to be targeted for investigation: (1) Coronavirus Aid, Relief and Economic Security (CARES) Act programs, specifically the Paycheck Protection Program (PPP) and Economic Injury Disaster Loan Program (EIDL); (2) the federal government’s pandemic response in 2020; (3) “Big Tech” companies’ perceived monopolization and the spread of disinformation and extremism on social media platforms; and (4) the fossil fuel industry’s influence on the Trump administration and its impact on climate change.

    The Effectiveness and Use of CARES Act Stimulus Funds

    From March 2020 to March 2021, Congress appropriated more than $5 trillion to address the COVID-19 pandemic and support the US economy. More than $700 billion of those funds have been delivered to businesses and sole proprietors through the US Small Business Administration’s (SBA) PPP and more than $200 billion has been distributed through the agency’s EIDL program. A key aspect of each program in 2020, and now in 2021, is that Congress and the SBA allowed applicants to self-certify their eligibility for these business loans. As a result of the self-certification process, confusing regulatory guidance and rules from the SBA and Department of the Treasury—on top of unprecedented economic uncertainty—the SBA disbursed billions of dollars in loans to businesses that Congress—or at least some members—did not intend or want to receive such loans. The House Select Subcommittee on the Coronavirus Crisis has already sent letters to a number of PPP loan recipients demanding documents relating to their loan applications and certifications. Additionally, the Select Subcommittee continues to conduct oversight of the SBA’s administration of these programs, including the Trump administration’s communications with large banks and business groups. We expect that this oversight and scrutiny of loan recipients—especially those that are viewed as connected to private equity firms, hedge funds and public companies—to continue in 2021.

    The Federal Government’s Pandemic Response

    Personal Protective Equipment Contracts

    When the pandemic hit the United States in early 2020, the country was not prepared to protect its people. At the forefront of this failure was the lack of personal protective equipment (PPE) available to healthcare workers. Images circulated on social media and news sources of nurses and physicians wearing trash bags in lieu of proper PPE. In a belated effort to respond to the crisis, the Trump administration doled out billions of dollars in contracts to businesses to provide the needed PPE to various hospitals, clinics and Veterans Affairs homes throughout the country. This drew the ire of the Select Subcommittee in July 2020, which wrote letters demanding documents to certain agency heads and contractors and stated the following in a press release:

    Recent reports indicate that federal agencies awarded contracts to businesses that had political connections to the Trump Administration, lacked federal contracting experience and had been selected by the White House without competition or transparency. Some of these companies failed to provide the supplies promised. The Select Subcommittee is concerned that these contracting practices may have wasted taxpayer dollars and exacerbated shortages of critical supplies, contributing to the spread of the coronavirus and the death of Americans.

    As Congress obtains documents and communications from the executive branch that may not have been turned over during the prior administration, expect more scrutiny of former officials and businesses with whom they interacted on large PPE procurements.

    Nursing Homes

    As the COVID-19 pandemic took hold in 2020, legislators on both sides of the aisle and across multiple congressional committees held hearings and launched investigations related to nursing home policies during the pandemic. For example, in June 2020, the Select Subcommittee on the Coronavirus Crisis, led by House Majority Whip Jim Clyburn (D-SC), launched an investigation that included letters to the Centers for Medicare & Medicaid Services (CMS) and the nation’s five largest for-profit nursing home companies. Also in June, the House Ways and Means Health Subcommittee held a similarly themed hearing. On the other side of the aisle and also in June, Senator Chuck Grassley (R-IA) and Congressman Greg Walden (R-OR), then the Chairman of the Senate Finance Committee and the Ranking Member on the House Energy and Commerce Committee, respectively, asked the Health and Human Services (HHS) Office of Inspector General (OIG) to initiate an investigation into whether five states (California, Michigan, New Jersey, New York and Pennsylvania) violated federal guidance in pressuring nursing home facilities to accept patients who tested positive for COVID-19. Ongoing investigations by the Select Subcommittee on Coronavirus, along with other standing committees with jurisdiction over nursing home issues, are possible in 2021.

    Hospitals

    Also on the front lines during the COVID-19 pandemic, US hospitals may face increased scrutiny with respect to various aspects of pandemic response. Hospitals’ receipt and use of federal funding provided through the CARES Act, such as the Provider Relief Fund, may also face heightened examination.

    “Big Tech” Companies

    Antitrust/Monopolization Investigations

    Last October, after a 16-month investigation, the House Judiciary Subcommittee on Antitrust, Commercial and Administrative Law released a 450-page majority staff report alleging monopolistic practices of leading technology companies and recommending sweeping changes to antitrust laws. Democrats have already revived this inquiry and will look to translate their findings and recommendations into legislation. In February, the Subcommittee announced that it will be holding a series of hearings to consider legislative proposals “to address the rise and abuse of market power online and to modernize the antitrust laws.”

    Social Media

    The spread of disinformation on social media has been an area of intense interest among Democrats over the last several years and apparently will continue to be. Last month, the House Oversight and Reform Committee sent a letter to the social networking company Parler regarding the platform’s involvement in the lead-up to the Capitol insurrection on January 6 and concerns about the spread of Russian disinformation. In addition, the House Energy & Commerce Committee held a hearing on March 25, 2021, on “misinformation and disinformation plaguing online platforms” during which the chief operating officers of several leading technology companies testified. Look for Congress to continue its focus on the tech industry over the next two years on issues ranging from antitrust to privacy, cybersecurity and the spread of disinformation and extremism.

    Fossil Fuel Companies and Climate Change

    After four years of the Trump administration rolling back the Obama administration’s progressive climate change policies, Democrats in Congress are eager to shine a light on the perceived influence of fossil fuel industries on those rollbacks. For example, Senator Sheldon Whitehouse (D-RI) sent a letter on March 15, 2021, to the Department of Justice (DOJ) seeking information relating to a number of matters, including the DOJ’s Antitrust Division’s investigation into certain automakers’ agreement with the State of California in 2019 to adjust state fuel economy standards. According to Senator Whitehouse, the Antitrust Division’s investigation came after “President Trump sent tweets decrying the arrangement[,]” “as it foiled the fossil fuel industry’s plot to blow up the fuel efficiency standards regime.” Senator Whitehouse further alleged that the Antitrust Division’s investigation and letters to the automakers’ “true origin may have been the White House and that they were perhaps devised in concert with Marathon Petroleum and the oil industry in a joint political effort.”

    Expect this inquiry to be among the first of many that Senator Whitehouse and Democrat-controlled committees launch into the fossil fuel industry during the 117th Congress. These inquiries are likely to focus on the fossil fuel industry’s impact on climate change and its political activities—both direct contributions to candidates as well as “dark” money used in lobbying efforts and advertisements.

    ***

    McDermott’s Congressional Investigations practice has the personnel and experience to help individuals and organizations navigate the various challenges presented by congressional oversight. Our professionals have served at all levels of congressional staff—and on both sides of the aisle—including as chief counsel to the House Energy & Commerce Committee and counsel to the Senate Judiciary Committee and as aides to high-ranking members of Congress. Additionally, our team has represented clients from many different industries before almost every committee of Congress. Whether you or your company receives a one-off oversight letter or becomes the target of a full-blown investigation, our team is prepared to help.

    Authors

    Llewelyn M. Engel

    Partner

    Washington, DC

    Peter M. Routh

    Associate

    Washington, DC

    More insights

  • The Next Wave of COVID-Related Criminal And Civil Enforcement Actions Is Starting

    The Next Wave of COVID-Related Criminal And Civil Enforcement Actions Is Starting

    ARTICLE / CLIENT ALERT

    The Next Wave of COVID-Related Criminal And Civil Enforcement Actions Is Starting

    March 29, 2021

    Read time: 12 min

    Key takeaways
    Overview

    Given the rapid pace and volume of economic aid allocated by Congress to combat the COVID-19 pandemic and its economic impacts, it is no surprise that the federal government has focused heavily on identifying and prosecuting COVID-related fraudulent conduct. US law enforcement agencies now appear poised to launch a new wave of investigations to identify and pursue additional civil and criminal actions against alleged wrongdoers. The complex, rushed nature of many COVID-related aid programs, however, may make it difficult for prosecutors to pursue more complex cases where conduct is less-obviously fraudulent.

    In depth

    With the recent passage of the American Rescue Plan, Congress will have allocated more than $5 trillion dollars to combat the COVID-19 pandemic and related economic crisis. The influx of unprecedented amounts of government funds into the economy has already led to a large number of criminal and civil enforcement actions and investigations. To date, the Department of Justice (DOJ) has criminally charged 474 defendants in COVID-related fraud cases, with potential losses of over $569 million. However, most of those prosecutions have focused on the low-hanging fruit, i.e., blatant instances of fraud or abuse. Those prosecutions are likely just the tip of the enforcement iceberg.

    On March 26, 2021, the DOJ emphasized its ongoing commitment to pursuing COVID-related criminal and civil enforcement actions. There are indications that this next wave of COVID-related government enforcement actions will increasingly focus on large-scale, complex fraud investigations and will involve the more frequent use of civil fraud statutes, such as the False Claims Act (FCA), the Anti-Kickback Statute (AKS), and the Financial Institutions Reform, Recovery and Enforcement Act of 1989 (FIRREA). Indeed, it appears that such a shift has already begun.

    In 2021, one can expect to see increased COVID-related criminal and civil enforcement actions in four areas: (1) the Paycheck Protection Program, (2) healthcare, (3) securities, and (4) government contracts and procurement. Many of these enforcement actions, however, may face significant challenges given the speed in which the relief programs were implemented and the lack of clear rules, regulations and guidance from federal agencies.

    The Paycheck Protection Program

    For the past year, the Department of Justice (DOJ) Fraud Section primarily focused on combatting fraud in connection with the Paycheck Protection Program (PPP). The PPP was created as part of the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) to provide to small businesses forgivable loans of up to $10 million. Between March and April 2020, Congress authorized approximately $670 billion in funding for PPP loans. In December 2020, Congress authorized an additional $284 billion for first- and second-time PPP borrowers.

    The DOJ’s Fraud Section has already charged 109 defendants in 74 PPP loan fraud criminal cases, involving total attempted losses of more than $268 million. There have also been a large number of similar fraud prosecutions relating to Economic Injury Disaster Loans (EIDL) program. Many of these prosecutions arose from data analysis. And PPP or EIDL fraud prosecutions to date have typically involved three categories of easily identifiable fraudulent conduct: (1) obtaining PPP loans using fictitious companies and/or stolen identities, (2) relying upon inflated employment figures and/or submitting fake payroll documents or tax returns, and (3) using PPP loan funds for improper purchases such as luxury cars and homes.

    Although similar PPP loan fraud prosecutions will continue in 2021 (particularly as new PPP loans are issued and businesses file loan forgiveness applications), the next wave of PPP loan fraud investigations will likely target more complex fraudulent conduct and focus on larger PPP loans or single corporate groups that received multiple PPP loans. The DOJ is also expected to increase its use of civil enforcement actions under the FCA and FIRREA to target PPP loan fraud. Indeed, in January 2021, the DOJ announced the first civil settlement of FCA and FIRREA claims in a case involving a fraudulent PPP loan.

    Another issue that may lead to increased civil enforcement actions is the requirement that businesses certify in “good faith” that the PPP loan was necessary to maintain ongoing operations. The SBA will be auditing all PPP loans exceeding $2 million and is currently requiring all businesses that received such loans to submit a “necessity questionnaire.” Although false statements made in connection with an SBA audit or on the necessity questionnaire can lead to criminal exposure, the government is more likely to pursue civil remedies given the difficulty in proving the falsity of a borrower’s belief that a PPP loan was “necessary.” The DOJ may also be hesitant to pursue criminal charges when a business made inaccurate statements in connection with the necessity questionnaire or did not meet the technical PPP eligibility requirements, but nevertheless used the PPP loan funds for their intended purpose.

    Healthcare Fraud

    One area in which there has yet to be significant COVID-related enforcement actions is in the healthcare space. This, however, is certain to change in the near future as the DOJ and Department of Health & Human Services (HHS) analyze additional Medicare claims data and/or more whistleblower qui tam complaints are filed. As a result, there will likely be significant increases in both criminal and civil healthcare fraud enforcement actions in 2021.

    So far, there have been only a small handful of healthcare fraud prosecutions relating to COVID-19. The first two COVID-related healthcare fraud prosecutions involved bundling COVID-19 tests with other medically unnecessary “add-on” tests, an area of concern HHS identified at outset of the pandemic. The DOJ also recently charged two pharmacy owners with using COVID-19 emergency override billing codes in order to bill Medicare $30 million for expensive cancer medication that was never purchased, prescribed or dispensed to patients.

    But the DOJ’s focus appears to be expanding. Last month, the DOJ brought the first criminal prosecution in the country involving the Provider Relief Fund. The Provider Relief Fund was created as part of the CARES Act to provide direct payments to healthcare providers for expenses and lost revenue relating to COVID-19. The government has allocated $178 billion in financial assistance as part of the Provider Relief Fund, and has already distributed more than $100 billion. Given the large amounts of money distributed through the Provider Relief Fund, such prosecutions will likely increase in frequency in 2021, particularly as providers begin submitting to HHS required reports regarding their use of the funds. Also, the DOJ recently reiterated that its Civil Division will be using the FCA to aggressively pursue COVID-related healthcare fraud cases, including cases involving the Provider Relief Fund and telehealth services (the use of which expanded significantly during the COVID-19 pandemic).

    Civil healthcare fraud enforcement actions under the FCA are also likely to increase in the near future because of the DOJ’s increasing use of data analytics to identify potential fraud. Indeed, data analytics is already proving to be a game changer. Although qui tam relators continue to be the primary source of FCA cases, last year the DOJ initiated 250 FCA cases on its own—100 more cases than the DOJ initiated in 2019, and the most non-qui-tam FCA cases filed in nearly 30 years. As a result, there were a record 922 federal FCA cases filed in 2020, more than 60% of which were healthcare related. The combination of a more proactive DOJ and increased federal funding for healthcare providers due to COVID-19 could create a perfect storm and lead to an unprecedented increase in FCA healthcare fraud cases.

    Securities Fraud

    At the outset of the COVID-19 pandemic, the Securities & Exchange Commission (SEC) primarily focused on preventing simpler COVID-related fraud schemes targeting “Main Street” investors. But as the economy continues to recover in 2021, the SEC may increasingly focus on whether public companies accurately disclosed to their investors the impact the COVID-19 pandemic had on their finances and operations.

    Just as with fraudulent PPP loans, the SEC enforcement actions have focused on the low-hanging fruit. The vast majority of COVID-related securities enforcement actions to date have involved pump-and-dump schemes involving microcap or penny stocks and/or blatant false statements that artificially inflated a company’s stock price. For example, between March and May 2020, the SEC suspended trading in more than 30 different securities due to false or misleading claims regarding their ability to sell PPE or to develop COVID-19 tests or treatments. The SEC’s initial trading suspensions have led to a number of subsequent SEC civil complaints, and some parallel criminal prosecutions.

    The SEC’s recent civil settlement with The Cheesecake Factory, however, is likely a preview of the different types of securities enforcement actions that are coming down the road. In December 2020, the SEC announced it reached a $125,000 settlement with The Cheesecake Factory for making misleading disclosures about the impact of the COVID-19 on its business operations and financial condition. This was the first time since the pandemic started that the SEC has brought such claims. As the long-term financial impact of COVID-19 on businesses becomes clearer, similar SEC actions based on false, misleading or inadequate financial disclosures are likely to increase in frequency.

    Government Contracting and Procurement Fraud

    During the past year there have been an extensive amount of government contracts and grants awarded to combat the COVID-19 pandemic. Federal agencies have already allocated more than $53 billion in contract spending relating to COVID-19, and that number will certainly increase in 2021 and with the passage of American Rescue Plan. However, there have also been persistent reports of fraud in connection with these COVID-related government contracts and grants. The DOJ has always focused heavily on government contracting and procurement fraud, and one can expect that criminal and civil enforcement activity in this area will intensify in 2021.

    The DOJ brought the first significant procurement fraud prosecution relating to COVID-19 in January 2021. Robert Stewart, Jr., the CEO of a Virginia-based business, had agreed to sell more than $38 million of 19 types of personal protective equipment (PPE), including N95 masks, to the Federal Emergency Management Agency (FEMA) and the Department of Veterans Affairs (VA), even though his company did not possess any PPE to sell. Stewart pleaded guilty to false statements to government agencies, wire fraud and theft of government funds.

    The Stewart case will likely be the first of many procurement fraud prosecutions to come in 2021. For example, as of November 2020, the DOJ’s Procurement Collusion Strike Force (PCSF) had already opened more than two dozen grand jury investigations, many of which likely involve COVID-related procurement fraud. The PCSF was formed in 2019 to investigate and prosecute government procurement antitrust and fraud crimes. And although the PCSF’s primary focus remains antitrust actions, the PCSF has been working closely with the Pandemic Response Accountability Committee (PRAC) to investigate other COVID-related procurement fraud offenses.

    The reality is that any company that received federal funds relating to COVID-19, either directly from the federal government or indirectly through state and local governments, could find itself subject to a criminal or civil investigation if the funds were not used appropriately or false statements were made in the contracting or grant processes. On the criminal side, there are a plethora of statutes the government can use to prosecute procurement fraud offenses. On the civil side, companies will continue to see claims brought under the FCA and AKS.

    For the past year, federal, state and local governments have understandably been focused on allocating and spending billions of dollars in relief funds meant to combat COVID-19 and the resulting economic downturn. But as this money is distributed, government contracts are fulfilled and contractors are audited, the government will increasingly turn its attention to identifying and prosecuting fraud or abuse. Those investigations are likely already in progress and will continue to increase in scope, frequency and intensity during 2021.

    The Nature of the COVID-19 Relief Programs Will Pose Challenges for Prosecutors and Present Opportunities for Defense Counsel

    Although the availability of more than $5 trillion in COVID-19 relief funds will lead to increased enforcement actions, the scope and complexity of the relief programs and the speed with which those programs were implemented will present numerous challenges for prosecutors or regulators pursuing those cases. Most criminal prosecutions will require the government to prove a defendant acted with intent to defraud, and civil enforcement actions, such as FCA claims, will at a minimum require proof a defendant acted knowingly. In many complex cases, this will be easier said than done.

    For example, when implementing the PPP, the SBA appeared to focus more heavily on getting loans approved and funding to businesses than on making sure there was clear guidance to borrowers and lenders about the program requirements. Certain program requirements changed each time Congress authorized additional PPP funding and the SBA has frequently issued new interim final rules on a variety of topics. As a result of these frequent rule changes, the SBA has already published seven different versions of its Frequently Asked Questions. Thus, should the government pursue civil actions regarding technical violations of the PPP, the government may have difficulty proving that the company understood the applicable rules and program requirements when it submitted its applications.

    Similarly, in the healthcare space, HHS has frequently changed or modified various requirements and statutory or regulatory standards in an effort to ease the regulatory burden during the pandemic. These regulatory changes will likewise make proving knowledge or intent increasingly difficult in certain cases.

    In conclusion, although COVID-19 enforcement actions and investigations will increase in frequency, scope and complexity during 2021, the success of such actions is not assured. Once the government moves beyond prosecuting obviously fraudulent conduct and focuses on more complex cases or technical legal violations, any ambiguity in the applicable rules or regulations could be used as a powerful defense.

    Authors

    Julian L. André

    Partner

    Los Angeles

    More insights

  • Because of FDII, Every Global Supply Chain Should Consider A U.S. C Corporation

    Because of FDII, Every Global Supply Chain Should Consider A U.S. C Corporation

    ARTICLE

    Because of FDII, Every Global Supply Chain Should Consider A U.S. C Corporation

    March 29, 2021

    Read time: 1 min

    Key takeaways
    Overview
    In depth
    Authors
    More insights